Plant, yeast, even mammalian cells could be engineered into living detectors of virtually any molecule of interest to improve environmental monitoring, metabolic production of pharmaceuticals, and more
Synthetically engineered biosensors, which can be designed to detect and signal the presence of specific small molecule compounds, have already unlocked many potential applications by harnessing bacterial cells such as E. coli to sense toxins or enable bioproduction of valuable commodities including fuel, plastics, and pharmaceuticals. As of yet, however, scientists have been challenged to leverage biosensors for use in eukaryotic cells — which comprise yeast, plants and animals — because strategies-to-date are limited in the molecules they can detect and the signals they can produce.
But now, a team of researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School (HMS) led by George Church, Ph.D., has developed a new method for engineering a broad range of biosensors to detect and signal virtually any desired molecule using living eukaryotic cells. Church, who is a Wyss Core Faculty member and the Robert Winthrop Professor of Genetics at HMS, and his team reported their findings in the journal eLife.
To test their new method, the team experimentally engineered yeast, plant, and mammalian cells to contain customizable ligand-binding domains (LBDs), which are receptors for hormones and other types of small molecules. These custom LBDs are tailored so that they only bind and “detect” a specific molecule of interest, such as the human hormone progesterone or the drug digoxin. Once the LBD binds to the target molecule, a secondary “signal” component fused to the LBD can be programmed to emit fluorescence or regulate gene expression. The components of this biosensor — the LBD in combination with the fluorescent or genetic signal — degrade and fade away if the target molecule is not identified.
Strikingly, the team successfully engineered Arabidopsis plants to act as multicellular botanical biosensors, containing a custom LBD to recognize the drug digoxin and a luminescent signal protein to emit light when digoxin is “detected”. These Arabidopsis biosensors gave off fluorescence when the plants were exposed to digoxin, proving that whole organisms can visually light up to signal detection of an arbitrary molecule.
“Like many eukaryotic organisms, plants are full of diverse hormones that make it challenging to sense and respond to a specific hormone of interest,” said Dan Mandell, Ph.D., the study’s co-first author and a Wyss Institute Technology Development Fellow and Postdoctoral Research Fellow at HMS. “But using our strategy, the Arabidopsis plants we engineered exhibited a 50-fold increase in luminescence in the presence of digoxin — very easily visualized — which could inspire exciting future applications involving trees or plants that detect harmful environmental pollutants or toxins and give off a visible indicator.”
“Biosensors that can tell you about their environment are extremely useful for a broad range of applications,” said Church. “You can imagine if they were used in agricultural plants, they can tell you about the condition of the soil, the presence of toxins or pests that are bothering them.”
The team not only demonstrated its novel methodology in plants but also described its efficacy in turning yeast and mammalian cells into precise biosensors, which could one day be leveraged for use in industries that rely on the productivity of yeast or livestock, or for use as medical sensors. Overall, the method is extremely tunable and portable, meaning it can be used in a wide variety of organisms to detect a broad range of small molecules.
An additional capability of the new biosensing methodology is the ability to connect it to gene regulators instead of fluorescent proteins. Such biosensors could precisely regulate gene transcription in order to improve yields of small molecules in organisms used for industrial bioproduction. Yeast, for example, could therefore be engineered to produce a desired molecule from a renewable feedstock, and furthermore programmed to self-identify the most efficient individuals within a population of producers so that only the highest producing yeast would survive. In this way, a population of organisms leveraged for bioproduction of pharmaceuticals or other valuable molecules could quickly self-evolve to become extremely efficient and productive. The team in fact used this strategy to evolve yeast that can produce the hormone progesterone with several-fold higher yield.
The biosensors could have a direct impact on human health as well, given that the team also used their method to tightly regulate the gene editing mechanism CRISPR-Cas9 inside living human cells, a step towards preventing unintended changes to the genome during gene therapy.
“These new reprogramming capabilities developed by the Church team open up an entirely new realm where ordinary organisms can be transformed into extraordinary living cellular devices that can sense specific signals and produce appropriate responses, whether its enhancing production of biofuels or secreting a therapeutic when the cells sense inflammation or infection. It’s another great enabling capability that will undoubtedly advance the entire field of synthetic biology.,” said Wyss Institute Founding Director Donald Ingber, M.D., Ph.D., who is the Judah Folkman Professor of Vascular Biology at HMS and the Vascular Biology Program at Boston Children’s Hospital, as well as Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.
The Latest on: Synthetic biology
via Google News
The Latest on: Synthetic biology
- Twist Bioscience to Expand Oregon Lease, Supporting Future Growthon April 16, 2021 at 5:01 am
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has ...
- Synthetic Biology Tools Market Analysis Size, Growth and ComparisonRegions, Types and Applications 2021 to 2028 By Ameco Researchon April 16, 2021 at 3:02 am
The global Synthetic Biology Tools market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market The Global Synthetic Biology Tools market research report ...
- Synlogic Announces Pricing of Public Offering of Common Stockon April 16, 2021 at 3:00 am
Synlogic (NASDAQ:SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, ...
- Synlogic Announces Proposed Public Offering of Common Stockon April 15, 2021 at 1:02 pm
Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has commenced an ...
- Tech Moves: Adaptive Biotech co-founders join life sciences SPAC; new edtech execs; and moreon April 15, 2021 at 12:55 pm
Adaptive Biotechnologies co-founders and brothers Chad and Harlan Robins are among the directors of a new life sciences SPAC. The blank check company is called CM Life Sciences III Inc.
- Reconstitution of contractile actomyosin rings in vesicleson April 15, 2021 at 5:32 am
Cytoskeletal networks support and direct cell shape and guide intercellular transport, but relatively little is understood about the self-organization of cytoskeletal components on the scale of an ...
- Synthetic Biology Market 2021 Global Technology, Development, Industry Share, Size, Growth, Trends and COVID-19 Impact Analysis 2027on April 15, 2021 at 2:28 am
The global synthetic biology market is expected to exceed more than US$ 12.50 billion by 2024, at a CAGR of 20% in ...
- New Coalition Dedicated To Fostering American Synthetic Biology Manufacturing Launched Todayon April 14, 2021 at 6:30 am
Today, three leading synthetic biology companies announced the launch of the Synthetic Biology (SynBio) Coalition ( to ...
- Meet The Company Reprogramming The Future Of Synthetic Biologyon April 14, 2021 at 6:00 am
Bit.bio, a synthetic biology company based in Cambridge, UK, is radically reimagining what is possible with the engineering of mammalian cells.
- Pure Biologics Selects Twist Bioscience to Expand Phage Display Technology Capabilitieson April 14, 2021 at 5:00 am
About Twist Bioscience Corporation Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the ...
via Bing News